Performance Evaluation of a Modified Version of the Norudia Glycated Albumin Assay that Reduces Negative Interference

that of the previous one to two months [1,2].Compared to HbA1c, GA reflects rapid changes in glycemic control and is not affected by hematologic diseases [2].While GA has been widely adopted in Asian countries, its clinical significance in Caucasians was only recently validated [3].Our institute has been measuring GA with the Norudia GA assay (Sekisui Medical Co., Ltd., Tokyo, Japan) since 2018.When using the original version of the Norudia GA, the researchers noted certain cases with extremely low GA results inconsistent with the glycemic status of the corresponding patients.This phenomenon led to the development of a modified version of the Norudia GA assay.This study evaluated the analytical performance of the modified version of the Norudia GA assay (Sekisui Medical Co., Ltd.) that aimed to resolve false negative results.